Perimeter Medical Imaging AI to Report Third Quarter Results
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) is set to deliver its financial results for the third quarter of 2025 after the market closes on a Wednesday in November. As a forefront player in medical technology, Perimeter is dedicated to revolutionizing cancer surgery with breakthrough imaging tools that meet critical medical needs.
Details of the Upcoming Conference Call
When to Tune In
The third quarter results will be discussed during a conference call scheduled for 5:00 pm Eastern Time. This will provide an excellent opportunity for stakeholders to gain insights into the company's performance and future direction.
How to Connect
Interested participants can join the call by dialing either 1-800-717-1738 for Canadian and U.S. callers or 1-646-307-1865 for those calling internationally. This interactive session will clarify financial metrics and significant developments within Perimeter.
About Perimeter Medical Imaging AI, Inc.
Headquartered in Toronto and Dallas, Perimeter Medical Imaging AI is focused on transforming the surgical landscape for cancer treatment. Their advanced imaging technologies include the FDA-cleared Perimeter S-Series OCT system, which offers real-time visualization of excised tissues at the cellular level.
The company is also advancing its next-generation Perimeter B-Series OCT with ImgAssist AI. This device has been evaluated in a pivotal clinical trial and has garnered a substantial grant from a state organization, showcasing its potential impact on cancer diagnosis and surgical outcomes.
Innovating Cancer Surgery
Perimeter’s commitment to innovation is evident in its products that enhance the precision of cancer surgeries, aiding in the critical evaluation of tissue margins. The FDA-approved S-Series represents a significant advancement in imaging technologies, while the investigational B-Series has been recognized for its potential in improving patient outcomes.
Contributions to Cancer Research
Perimeter's initiatives extend beyond commercial success. With strong backing from research institutions, their projects aim to minimize the risks associated with cancer surgeries, providing physicians with better tools for real-time analysis of surgical samples.
With the ongoing support of grants, including those aimed at fostering innovative technologies, Perimeter is on a mission to improve healthcare services in oncology.
Current Developments
The company's stock symbol “PINK” signifies its association with breast cancer awareness initiatives, enhancing public engagement and support for the vital work done in cancer research and technology.
Contact Details for Further Information
For inquiries, interested parties can reach out to Stephen Kilmer, who leads investor relations at Perimeter Medical Imaging AI, through various channels. He is available at 647-872-4849. Additionally, Adrian Mendes, the Chief Executive Officer, can be contacted toll-free at 888-988-7465.
Frequently Asked Questions
What financial results will Perimeter Medical Imaging report?
Perimeter Medical Imaging will report its third quarter financial results, detailing key financial metrics and operational updates.
When is the conference call scheduled?
The conference call to discuss the results will take place at 5:00 pm Eastern Time.
How can I join the conference call?
Participants can join the call by dialing 1-800-717-1738 or 1-646-307-1865.
What technologies does Perimeter develop?
Perimeter develops advanced imaging technologies for cancer surgeries, including the Perimeter S-Series and the investigational B-Series with ImgAssist AI.
How does Perimeter support cancer research?
The company actively participates in cancer research through grants and collaborative projects aimed at enhancing surgical precision and patient outcomes.
